---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-043347"
form_type: "8-K"
ticker: "PRLD"
cik: "0001678660"
company_name: "Prelude Therapeutics Inc"
filed_at: "2024-04-10T23:59:59+00:00"
generated_at: "2026-06-04T00:26:15.662511+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Prelude Therapeutics CFO departs; Bryant Lim named interim CFO

## Summary
- Laurent Chardonnet ceased as CFO on April 8, 2024; he will consult at $500/hr through Oct 4, 2024.
- Bryant D. Lim, current Chief Legal Officer and Secretary, appointed interim CFO.
- Chardonnet receives severance of $333,750 (9 months base salary) plus COBRA subsidy.
- Consulting fee up to $50,000; Chardonnet's equity awards continue vesting.

## SEC filing metadata
- accession: 0000950170-24-043347
- form_type: 8-K
- ticker: PRLD
- cik: 0001678660
- company_name: Prelude Therapeutics Inc
- filed_at: 2024-04-10T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000095017024043347/0000950170-24-043347-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000095017024043347/prld-20240408.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-043347
- JSON: https://secwatch.observer/filing/0000950170-24-043347.json
- Plain text: https://secwatch.observer/filing/0000950170-24-043347.txt

## Key facts
- Executive change
  Bryant D. Lim was appointed as interim Chief Financial Officer at Prelude Therapeutics Inc.
  - Action: appointed
  - Role: interim Chief Financial Officer
  source text: Effective as of the Effective Date, the Board of Directors of the Company appointed Bryant D. Lim, the Company’s Chief Legal Officer and Corporate Secretary, as its interim Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1678660/000095017024043347/0000950170-24-043347-index.htm
- Executive change
  Laurent Chardonnet departed as Chief Financial Officer at Prelude Therapeutics Inc.
  - Action: agreed that he will no longer serve
  - Role: Chief Financial Officer
  source text: On April 8, 2024 (the “Effective Date”), Prelude Therapeutics Incorporated (the “Company”) and Laurent Chardonnet, the Company’s Chief Financial Officer, agreed that he will no longer serve as the Company’s Chief Financial Officer, effective as of the Effective Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1678660/000095017024043347/0000950170-24-043347-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.